|
Sanofi
Nov 6, 2015 19:58:55 GMT -5
Post by rockstarrick on Nov 6, 2015 19:58:55 GMT -5
Darn it. Missed the hour window to delete my comment and act like I'm not math challenged. Guess I shouldn't drink so much at work As Emily Litella would say... "Never Mind" I resemble that remark I always wondered what that edit button was for ??
|
|
|
Post by dreamboatcruise on Nov 6, 2015 20:00:45 GMT -5
afrizzle... both were Gilda Radner, but it was the Emily Litella character on the Weekend Updates that said that. fedakd... setting aside my lapse of mental capacity on calculating profit. The 21 P/E is what SNY trades at. It would be hard for them to justify paying more than that if they were just acquiring the stake in Afrezza they don't own. Not if it's 21x the assumed profits of Afrezza years from now. SNY isn't magically going to acquire biotech type P/E for themselves simply by acquiring the remaining stake of Afrezza. This is why shareholders in the long run are likely better off having MNKD retain this stake... then we get the potential benefit of a higher biotec multiple being applied. Of course that assumes no liquidity problem and further dilution.
|
|
|
Post by savzak on Nov 6, 2015 21:35:13 GMT -5
Darn it. Missed the hour window to delete my comment and act like I'm not math challenged. Guess I shouldn't drink so much at work As Emily Litella would say... "Never Mind" Did you mean Rosanne Rosannadanna? Nope. Emily Litella.
|
|
|
Post by thekindaguyiyam on Nov 7, 2015 0:52:05 GMT -5
"And although its inhaled insulin product developed with MannKind Corporation (MNKD) has gotten off to a slow start, many analysts think it’s only a matter of time before Sanofi works things out with insurers and the public gets hold of a diabetic treatment that doesn’t involve shots." thanks for the post
|
|